Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783525 | 0.92 | HDAC4 (0.51) | ENPP2KDM4EALDH1A1MGLLHDAC4 | |
| SCHEMBL3786808 | 0.92 | HDAC4 (0.47) | ENPP2KDM4EALDH1A1MGLLHDAC4 | |
| SCHEMBL3784746 | 0.90 | KMO (0.53) | ENPP2KDM4EALDH1A1MGLLHDAC4 | |
| SCHEMBL32669062 | 0.89 | ENPP2 (0.42) | ENPP2KDM4EALDH1A1MGLLHDAC4 | |
| SCHEMBL29954777 | 0.84 | ENPP2 (0.45) | ENPP2KDM4EALDH1A1MGLLHDAC4 | |
| SCHEMBL19384201 | 0.82 | ENPP2 (0.40) | ENPP2KDM4EALDH1A1MGLLHDAC4 | |
| SCHEMBL29186356 | 0.82 | LPL (0.46) | ALDH1A1 | |
| SCHEMBL29186359 | 0.82 | LPL (0.46) | ALDH1A1 | |
| SCHEMBL30767881 | 0.82 | LPL (0.46) | ALDH1A1 | |
| SCHEMBL3787015 | 0.80 | ESR2 (0.33) | ENPP2KDM4EALDH1A1CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110551147-B | Synthetic method of 3-cyclopropylphenylboronic acid | 蚌埠产品质量监督检验研究院 | 2021-11-26 | — | — | CN | claimed |
| CN-110551147-A | synthetic method of 3-cyclopropylphenylboronic acid | BENGBU PRODUCT QUALITY AND INSPECTION INST | 2019-12-10 | — | — | CN | claimed |
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | GENESIS THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4602043-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMA S.A. (CH) | 2024-10-03 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024083086-A1 | BICYCLIC DERIVATIVE INTEGRIN INHIBITOR | 上海如凌生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| WO-2024081889-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20190276443-A1 | INDOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3529241-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | GENETECH, INC. | 2019-08-22 | — | — | US | disclosed |
| WO-2018093698-A1 | INDOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018073602-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | ALMAC DISCOVERY LIMITED (GB) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018021977-A1 | GLYCINE METABOLISM MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | WO | disclosed |
| WO-2017108204-A1 | NOVEL SUBSTITUTED SPIRO-[INDOLINE HETEROCYCLOALKANE] COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Grünenthal GmbH (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276443-A1 | INDOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | DGAT2, DGAT1, MOGAT2 | ENPP2 410/4885KDM4E 2602/4885ALDH1A1 758/4885 |
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | USP7, USP5, UBA7 | ENPP2 2104/4885KDM4E 673/4885ALDH1A1 1201/4885 |
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | PIK3R4, PIK3R1, PIK3R5 | ENPP2 811/4885KDM4E 3172/4885ALDH1A1 2415/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ENPP2 1920/4885KDM4E 2606/4885ALDH1A1 4339/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ENPP2 306/4885KDM4E 3568/4885ALDH1A1 472/4885 |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | GRM7, GRM2, GRM1 | ENPP2 910/4885KDM4E 2192/4885ALDH1A1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.